Breast Cancer Research and Treatment最新文献

{"title":"High-resolution microCT to assess breast microcalcification morphometry by histologic lesion subtype and radiologic classification.","authors":"Sarah Schrup, Santo Maimone, Michael Villalba, Robert A Vierkant, Stacey J Winham, Bryan McCauley, Matthew R Jensen, Tanya Hoskin, Lisa Seymour, Denice Gehling, Jessica Fischer, Kush Lohani, Celine M Vachon, Derek C Radisky, Laura Pacheco-Spann, Ruby Ethridge, Amy C Degnim, Mark E Sherman","doi":"10.1007/s10549-025-07792-6","DOIUrl":"10.1007/s10549-025-07792-6","url":null,"abstract":"<p><strong>Purpose: </strong>To assess associations of 3D morphometry of breast calcifications, determined using high-resolution microCT, with underlying histopathology and evaluate the potential for classifying tissue calcifications as an aid in optimizing identification and diagnosis of the most severe pathology in a biopsy.</p><p><strong>Methods: </strong>We compared morphometry of calcifications in tissue blocks (n = 156) of benign breast disease (n = 74), ductal carcinoma in situ (n = 39), and ductal carcinoma in situ with invasive breast cancer (n = 43) using (10 µm) microCT. Matched sections were reviewed microscopically to define lesion(s) in which calcifications were embedded. 3D reconstructions of calcifications were reviewed independently by two masked radiologists to assess the need for biopsy and calcification morphology. Calcification morphometry was compared to pathologic diagnosis using linear mixed models.</p><p><strong>Results: </strong>A total of 12,216 calcifications (IQR 9-66 per specimen) were analyzed. Individual breast cancer-associated calcifications were significantly larger than benign breast disease-associated calcifications (p_adjusted = 0.012) and calcification volume was positively associated with grade of ductal carcinoma in situ (P_trend = 0.009). Structure model index revealed more cylindrical shape in breast cancer calcifications versus benign breast disease calcifications (p_adjusted = 0.008). Re-analysis by the specific microscopic lesion containing the calcification, rather than the most severe diagnosis per biopsy, strengthened associations. Radiologists agreed on biopsy recommendation in 92% of microCT images, while achieving sensitivities of 53.1% and 54.3%. and specificities of 50.0% and 54.1%.</p><p><strong>Conclusion: </strong>Our analysis provides proof-of-concept that morphometry of tissue calcifications varies by lesion type, suggesting that future studies may enable development of a pathologic classification linked to diagnosis and mammographic findings.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"49-58"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of intermittent discontinuation cyclin-dependent kinase inhibitors on metastatic breast cancer during Lebanon's economic crisis.","authors":"Nadim Elias, Fadi El Karak, Nahed Damaj, Adel Hajj, Hampig Kourie, Roland Eid, Joseph Kattan","doi":"10.1007/s10549-025-07794-4","DOIUrl":"10.1007/s10549-025-07794-4","url":null,"abstract":"<p><strong>Introduction: </strong>This study examines the intermittent discontinuation of palbociclib based on its availability and its clinical outcomes during the Lebanese economic crisis in patients with metastatic Breast Cancer (BC) HR+ between the years 2019 and 2023.</p><p><strong>Methods: </strong>This study carries out a retrospective analysis on 46 patients treated with palbociclib - Letrozole during the years 2019 and 2023 in Lebanon. It used descriptive tables and figures to summarize demographic, clinical, and outcome characteristics. It analyzed the data using Student T test for parametric variables, Wilcoxon and Kruskal-Wallis tests for non-parametric variables, and Chi-squared and Fisher tests for qualitative variables. Pearson's correlation and regression models were used to associate between the intermittent administration of palbociclib and its clinical outcomes.</p><p><strong>Results: </strong>Our sample had a mean age of 59.33 +/-13.27 years. 87% had ductal carcinomas and 13% had lobular carcinomas. 52.2% of patients had treatment for their metastases prior to palbociclib, and a discontinuation was observed in 63.1 %. Intermittent discontinuation is associated with advanced age (p=0.048) and statistically reduces PFS (p=0.026). The intermittent drug intake also affects PFS (p=0.03) but has no effect on the disease progression.</p><p><strong>Conclusion: </strong>This study is the only research in the world focused on intermittent intake of palbociclib. The intermittent discontinuation of palbociclib is influenced by age and affects the PFS. These results highlight the significance of adherence and protocol compliance.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"113-120"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life during the COVID-19 pandemic and survival outcomes among breast cancer survivors.","authors":"Victoria Umutoni, Yijia Sun, Jincong Q Freeman, Fangyuan Zhao, Olufunmilayo I Olopade, Dezheng Huo","doi":"10.1007/s10549-025-07808-1","DOIUrl":"10.1007/s10549-025-07808-1","url":null,"abstract":"<p><strong>Background: </strong>Health-related quality of life (HRQoL) has long been recognized as a critical area of cancer research as it reflects patients' well-being, but less is known if HRQoL predicts survival outcomes in survivors of early stage breast cancer.</p><p><strong>Aims: </strong>We assessed racial disparities in HRQoL and the impact of HRQoL on survival outcomes in breast cancer survivors.</p><p><strong>Methods: </strong>This study included a total of 721 breast cancer survivors from the Chicago Multiethnic Epidemiologic Breast Cancer Cohort who completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument in 2020. We examined racial differences in FACT-B scores and patient characteristics correlated with FACT-B and its subscales using multiple linear regression. We used Cox regression to assess the associations between HRQoL assessments and survival outcomes.</p><p><strong>Results: </strong>Functional well-being score was lower in Black survivors than in White survivors (mean score: 19.6 vs. 20.9, P = 0.003). Being married was associated with a higher HRQoL score. Having a recurrence before interview and comorbidities worsened physical and emotional well-being. The total FACT-B score were significant predictors of both all-cause [hazard ratio (HR) = 0.68 per standard deviation, 95% CI 0.48-0.95] and breast cancer-specific mortality (HR = 0.57, 95% CI 0.37-0.88). Physical and functional well-being subscales were found to be associated with all-cause and breast cancer-specific mortality, and recurrence-free survival. Emotional well-being predicted breast cancer-specific mortality.</p><p><strong>Conclusions: </strong>Our findings highlighted racial disparities in HRQoL and HRQoL associated with survival outcomes in breast cancer, suggesting the need to reduce the disparities and examine the long-term impact of HRQoL on health outcomes in future studies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"205-214"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.","authors":"Rima Patel, Jami Fukui, Paula Klein, Erin Moshier, Hulya Kocyigit, Laura Fiedler, Weronika Bucwinska, Xiao Y Xing, Charles Shapiro, Anupama Goel, Julie Fasano, Theresa Shao, Aarti Bhardwaj, Esther Kim, Rita Vaccaro, Karen Lee, Eric Wilck, Amy Tiersten","doi":"10.1007/s10549-025-07802-7","DOIUrl":"10.1007/s10549-025-07802-7","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancers (TNBCs) are associated with a high frequency of PTEN loss, which can lead to activation of the mTOR pathway and tumor proliferation but may be reversible with the mTOR inhibitor everolimus. A prior phase II single-arm trial of carboplatin and everolimus in patients with advanced TNBC demonstrated good tolerability and preliminary efficacy.</p><p><strong>Patients and methods: </strong>A phase II randomized trial in patients with advanced TNBC, with 0-3 prior lines of therapy, was conducted. Patients were randomized 2:1 to receive carboplatin and everolimus or carboplatin alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and safety.</p><p><strong>Results: </strong>Between 2015 and 2022, 59 patients were randomized to carboplatin/everolimus (n = 38) or carboplatin alone (n = 21). The median age of the population was 62 years and 68% had received at least one prior line of therapy. Median PFS was significantly improved in patients who received carboplatin/everolimus (4.7 months) versus carboplatin alone (4.2 months; HR:0.49; 95% CI: 0.25-0.98; p = 0.0390). OS was 17.6 months with the combination and 14.6 months with carboplatin alone (HR:1.17; 95% CI: 0.59-2.30; p = 0.6593). The most common adverse events (AEs) on the combination included thrombocytopenia, anemia, leukopenia, and neutropenia.</p><p><strong>Conclusion: </strong>The combination of carboplatin and everolimus in this study reduced the risk of progression or death by 52%. The regimen was well tolerated and provides a promising treatment option for patients with advanced TNBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"159-170"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.","authors":"Julia G Cohn, Susan C Locke, Kris W Herring, Susan F Dent, Thomas W LeBlanc","doi":"10.1007/s10549-025-07805-4","DOIUrl":"10.1007/s10549-025-07805-4","url":null,"abstract":"<p><strong>Purpose: </strong>Metastatic breast cancer (MBC) is incurable, despite therapeutic advances, especially in hormone receptor positive (HR+) and human epidermal growth factor-2 negative (HER2-) disease. Specialist palliative care (SPC) is recommended to alleviate distress and reduce overly aggressive end-of-life (EoL) care. This study determined rates of SPC, hospice utilization, and aggressive EoL care in patients with HR+/HER2- MBC.</p><p><strong>Methods: </strong>A retrospective review was performed of patients with treatment naïve HR+/HER2- MBC treated with endocrine therapy and/or cyclin-dependent kinase 4 and 6 inhibitors at Duke Cancer Institute between January 2012 and December 2017. Variables pertaining to SPC and hospice use and EoL care outcomes up to March 2024 were collected. SPC and hospice utilization and EoL care data were analyzed with descriptive statistics.</p><p><strong>Results: </strong>Of 102 patients, 85 died during the study period, and over half (55%) received aggressive EoL care. Half had some form of SPC, and rates of aggressive EoL care were comparable between those who engaged with SPC and those who did not. The most common indicators of aggressive EoL care included multiple ED visits (28%) and hospital admissions (23%) in the last 30 days of life as well as in-hospital location of death (24%). Although 72% enrolled in hospice care, 9% of patients were on hospice for ≤ 3 days.</p><p><strong>Conclusion: </strong>This real-world study demonstrates that many patients with HR + /HER2- MBC receive aggressive EoL care despite some engaging with SPC and many enrolling in hospice. Interventions to decrease aggressive EoL care are needed for this population.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"181-190"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancer.","authors":"Ana-Alicia Beltran-Bless, Deanna Saunders, Lucas Clemons, Igor Machado, Gregory Pond, Brian Hutton, Khaled El-Emam, Sharon McGee, Terry L Ng, Marie-France Savard, John Hilton, Moira Rushton, Gail Larocque, Sabine Siesling, Andreanne Leblanc, Lisa Vandermeer, Mark Clemons","doi":"10.1007/s10549-025-07797-1","DOIUrl":"https://doi.org/10.1007/s10549-025-07797-1","url":null,"abstract":"<p><strong>Purpose: </strong>Clinico-pathologic (including nomograms) and genomic tools are widely used to determine prognosis and predict benefit from treatment in early breast cancer (EBC). However, little is reported on patient perceptions of these tools and whether they enhance understanding of their individual risk of recurrence or benefits from therapy.</p><p><strong>Methods: </strong>Patients with EBC were surveyed to evaluate the use of prognostic/predictive tools in clinical practice and their self-reported recurrence risk. Their actual risk of local, contralateral and distant recurrence was estimated using the INFLUENCE 2.0 tool. Information was also collected on key aspects that patients wanted these tools to address, as well as the anticipated benefits that would make receiving chemotherapy worthwhile from their perspective.</p><p><strong>Results: </strong>Completed surveys were received from 210 patients. Despite the use of NHS PREDICT 2.1 in 50% (105/210) and Oncotype DX in 10.9% (23/210) of patients, only 26% (45/210) stated they knew such a test had been performed. There was a mild association between patient self-assessment of distant recurrence risk and their actual risk as per INFLUENCE 2.0. When asked to rank what they wanted from prediction tools, patients identified chance of metastases (36.1%, 56/155) and chance of being disease free (31.3%, 46/147) as most important. Patients would consider chemotherapy if the survival benefit was ≥ 1% (31, 17.7%), 2-5% (23, 13.3%), 5-10% (24, 13.7%), ≥ 10% (36, 20.6%). These thresholds for benefit were significantly lower for patients who had received chemotherapy compared with those who had not.</p><p><strong>Conclusion: </strong>Despite the widespread use of prognostic and predictive tools, patients often appeared unaware that one had been used. This may in part explain the lack of relationship between self-perceived and actual risk of disease recurrence.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"214 1","pages":"87-99"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144942687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial.","authors":"Kate Lloyd, Lisa A Newman, Charity Glass, Esther R Ogayo, Erica L Mayer, Mariana Chavez-MacGregor, Rachel A Freedman, Tari A King, Elizabeth A Mittendorf, Olga Kantor","doi":"10.1007/s10549-025-07798-0","DOIUrl":"10.1007/s10549-025-07798-0","url":null,"abstract":"<p><strong>Purpose: </strong>Although triple-negative breast cancer (TNBC) is associated with increased risk for early locoregional (LRR) and distant recurrence (DR), it is unclear if there are racial differences in clinical outcomes. This study examines patterns of recurrence and breast cancer mortality (BCM) between Black and White women with high-risk TNBC treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) EA1311 randomized clinical trial.</p><p><strong>Methods: </strong>From 2015 to 2021, 415 patients with clinical stage II-III TNBC and residual disease after neoadjuvant chemotherapy (NAC) were randomized to adjuvant capecitabine or platinum chemotherapy. Overall, 363 patients with self-reported Black or White race were included in this analysis. LRR, DR, and BCM were analyzed by race using Kaplan-Meier curves for unadjusted estimates and Cox modeling for adjusted analyses.</p><p><strong>Results: </strong>Racial distribution included 66 (18.2%) Black and 297 (81.8%) White patients. Disease presentation, response to chemotherapy, and treatment arm were similar by race. Two-year estimated LRR was 27.1% in Black and 17.3% in White patients (p = 0.378), and 2-year estimated DR and BCM were similar by race. Models adjusted for race, age, stage, grade, treatment arm, and locoregional therapy did not identify race as an independent predictor of LRR, DR, or BCM.</p><p><strong>Conclusion: </strong>Among women with residual TNBC after NAC treated on this trial, there were no significant differences in LRR, DR, or BCM between Black and White patients at 2 years of follow-up. Despite the small cohort and short-term follow-up, our results suggest that treatment on a clinical trial may mitigate disparities in disease outcomes in TNBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"101-112"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival impact of adjuvant capecitabine in triple-negative breast cancer Latin American patients with residual disease: a real-world study.","authors":"Noiver Graciano, Lucelly López, Carlos A Rodriguez, Katherine Montoya, Javier Cortés","doi":"10.1007/s10549-025-07814-3","DOIUrl":"10.1007/s10549-025-07814-3","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with triple-negative breast cancer (TNBC) who do not achieve pathological complete response (non-pCR) after neoadjuvant chemotherapy (NACT) have a high-risk of relapse. While adjuvant capecitabine (AdjCape) has demonstrated improved overall survival (OS) and disease-free survival (DFS) in Asian populations, its effectiveness in non-Asian settings remains uncertain. We aimed to evaluate the effect of AdjCape on survival outcomes using real-world data from a Latin American population.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study (2008-2024) including 360 women with non-metastatic TNBC and non-pCR treated at a single institution. Propensity score matching (PSM) was applied to adjust for baseline differences. Cox regression models assessed the association of AdjCape with OS and DFS, and stratified analyses identified subgroups with differential treatment effects.</p><p><strong>Results: </strong>Among 360 patients, 106 (29.4%) received AdjCape. After PSM, 187 patients (72 AdjCape, 115 controls) were analyzed. AdjCape was not associated with improved OS (HR 0.79, 95% CI 0.51-1.23, p = 0.302) or DFS (HR 0.81, 95% CI 0.53-1.23, p = 0.321). However, significant benefit was observed in patients with high residual tumor burden (pT3-pT4: OS HR 0.29, p = 0.020; DFS HR 0.37, p = 0.044) and in those not receiving radiotherapy (DFS HR 0.47, p = 0.038).</p><p><strong>Conclusions: </strong>AdjCape did not improve OS or DFS in the overall TNBC non-pCR cohort but may offer benefit in patients with extensive residual disease or those not treated with radiotherapy. These findings highlight the need for individualized treatment strategies and further evaluation of capecitabine in the context of modern therapies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"265-275"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study.","authors":"Paola Gonzalo-Encabo, Anita Giobbie-Hurder, Dorothy D Sears, Erica L Mayer, Ann H Partridge, Philip D Poorvu, Adrienne G Waks, Anna M Tanasijevic, Tracy E Crane, Christina M Dieli-Conwright, Jennifer A Ligibel","doi":"10.1007/s10549-025-07803-6","DOIUrl":"10.1007/s10549-025-07803-6","url":null,"abstract":"<p><strong>Purpose: </strong>With limited lifestyle interventions available for women with metastatic breast cancer, we aimed to evaluate feasibility of a combined prolonged overnight fasting and exercise intervention in women with hormone receptor-positive metastatic breast cancer initiating treatment.</p><p><strong>Methods: </strong>Women with metastatic breast cancer initiating endocrine therapy plus targeted therapy were included in a single-arm pilot trial testing a combined 12-week prolonged nightly fasting and exercise intervention. Fasting goals included abstaining from calorie intake after 8 pm and fasting for 13 + hours 6 days per week; weekly exercise goals were 120 min of home-based aerobic exercise and 2 sessions of resistance exercise. Primary outcome was feasibility; secondary outcomes included patient-reported outcomes, cardiorespiratory fitness, and physical functioning. Measures were collected at baseline and 12-week time points.</p><p><strong>Results: </strong>Thirty-one women enrolled, and 27 completed both timepoint assessments. The feasibility goal for enrollment was met with 80% of participants enrolled within the first year. The fasting intervention was well tolerated, with 74.1% of women meeting the fasting goal. Only 40.7% of women achieved the aerobic exercise goal, and 18.5% met the strength training goal. Participants experienced a significant increase in quality of life post-intervention, with improvements in emotional (+ 8.3 ± 14.2 point; p = 0.003), cognitive (+ 4.9 ± 17.2 point; p = 0.04), social functioning (+ 8.6 ± 18.1 point; p = 0.02), dyspnea (- 12.3 ± 28.0 point; p = 0.002), and insomnia (- 16.0 ± 25.1 point; p < 0.001).</p><p><strong>Conclusion: </strong>This pilot study provides insights into the feasibility, safety, and preliminary efficacy of a 12-week combined fasting and exercise intervention in women with metastatic breast cancer initiating treatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"171-180"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.","authors":"Jenny Wei, Ashley Aller, Shiyun Zhu, Laurel A Habel, Catherine Lee, Jun Shan, Ninah Achacoso, Aida Shirazi, Marc A Emerson, Raymond Liu","doi":"10.1007/s10549-025-07811-6","DOIUrl":"10.1007/s10549-025-07811-6","url":null,"abstract":"<p><strong>Purpose: </strong>Extended adjuvant endocrine therapy (AET) beyond 5 years (up to 10 years) has been shown to be beneficial for some women with non-metastatic, hormone-receptor positive breast cancer. Much of our current understanding of adherence to and continuation with AET is derived from examining the 5 years after AET initiation and is limited beyond the first 5 years. To address this limitation, we conducted a retrospective cohort study examining AET adherence and time of continuation beyond 5 years among a large, real-world population in Northern California.</p><p><strong>Methods: </strong>We evaluated adherence to and continuation of extended AET among a cohort of 13,675 women diagnosed with Stage I-III, estrogen receptor positive (ER+) breast cancer between 2008 and 2017 treated at Kaiser Permanente Northern California. Adherence (medication possession ratio > 80%) and discontinuation (last pill possession date before a 180-day gap) of AET were examined.</p><p><strong>Results: </strong>Annual AET adherence declined gradually each year from 79% in year 1-60% in year 5 and dropped dramatically to 23% in year 6. Following year 6, annual adherence again declined gradually and was 10% in year 10. Similarly, there was a striking decline in AET continuation between year 5 (52%) and year 6 (20%). Only 4.5% continued to the end of year 10.</p><p><strong>Conclusions: </strong>We observed a dramatic drop in both adherence to and continuation with AET following year 5 into year 6. This potentially represents an inflection point for intervention to improve adherence to and continuation with extended AET among this patient population.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"239-246"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144942835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}